Luhan Pharmachem Co., Lt
Free supplier Enterprise Certification
- Free
supplier - 3rd
years
Free supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Lab/Research institutions
Tel: +86-871-65110906
Mobile: 86-131 6530761
Tel: +86-871-65110906
Fax:
Province/state: Yunnan
City: Kunming
Street: Room702, Building 2, 365 Dianchi Road, Kunming, Yunnan Province, P.R. China
MaxCard:
CAS NO.545445-44-1
3-MORPHOLIN-4-YL-1-[4-(2-OXWPIPERIDIN-1-YL)PHENYL]-5,6-DIHYDRO-1H-PYRIDIN-2-ONE (545445-44-1)
Information
The product is an Apixaban intemediate.
Quality
Advanced technology
Supper quality
Effective & safety package
Service
Professional and timely afte-sale service(replied within 12h)
COMPANY INFORMATION
Jinan Kangcheng Pharmaceutical Technology Co., Ltd.
Add:Jinan Area,China(Shandong) Pilot Free Trade Zone,China
The company focuses on the development and transfer of pharmaceutical technology. It is a modern enterprise integrating technology development, transfer and sales of APIs, pharmaceutical intermediates, and nutraceutical raw materials.
The company adheres to the principle of integrity and innovation, and provides customers with professional products and advanced technical services.
|
3-Morpholin-4-yl-1-[4-(2-oxopiperidin-1-yl)phenyl]-5,6-dihydro-1H-pyridin-2-one |
|
|
Product information |
English Name：3-Morpholin-4-yl-1-[4-(2-oxopiperidin-1-yl)phenyl]-5,6-dihydro-1H-pyridin-2-one |
|
English Alias：5,6-Dihydro-3-(4-morpholinyl)-1-[4-(2-oxo-1-piperidinyl) -phenyl]-2(1H)-pyridinone; Apixaban Intermediate |
|
|
Chinaese Name：5,6-二氢-3-(4-吗啉基)-1-[4-(2-氧代-1-哌啶基)苯基]-2(1H)-吡啶酮 Apixaban Intermediate |
|
|
Chinaese Alias：5,6-二氢-3-（4-吗啉基）-1- [4-（2-氧-1-哌啶基）苯基] -2（1H）-吡啶酮 阿哌沙班中间体 |
|
|
CAS号：545445-44-1 |
|
|
Formula：C20H25N3O3 |
|
|
Molecular weight：355.43 |
|
|
|
|
|
Appearance：White to off-white power |
|
|
Assay：98.0% |
|
|
Use&Pharmacology |
This product is an intermediate of Apixaban. Apixaban (ELIQUIS) is an oral selective activation factor X inhibitor, jointly developed by Pfizer and Bristol-Myers Squibb. Eliquis can prevent thrombosis, but the adverse effects of bleeding are lower than that of the old drug warfarin. It is used for thrombosis prevention in patients who have undergone hip or knee replacement surgery. In 2007, Bristol-Myers Squibb and Pfizer formally implemented a global strategic cooperation agreement to jointly develop and sell the anticoagulant product Apixaban; in 2011, it was the first to approve the use of elective hip joints in the 27 EU countries, Iceland and Norway. Prevention of venous thrombosis in adult patients undergoing knee replacement surgery; In January 2013, obtained the import drug license issued by the State Food and Drug Administration of China for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery Event (VTE), and then officially listed in China in April 2013. Apixaban is a new type of oral anticoagulant, a new type of oral factor Xa inhibitor, and a drug used to prevent and treat blood clots. The recommended dose is 2.5 mg, taken orally twice a day, which can effectively prevent venous thromboembolism without increasing the risk of bleeding. There is no need for routine monitoring of coagulation function and no dose adjustment. |
|
Package&Storage |
Package：1kg/bag, 10kg/drum, 25kg/drum (on request) |
|
Storage&Validity：Cool, shading, dry and sealed/2years |
|
